Panag Pharma Inc., a subsidiary of Tetra Bio-Pharma Inc., today announced completion of Panag 001, its Phase 3 clinical trial evaluating the safety and efficacy of Topical-A, now branded as Awaye™ for the treatment of pain caused by osteoarthritis of the knee.
Tetra Bio-Pharma Inc. will present key findings from its three Phase 1 and its Phase 2 cancer and non cancer investigational trials with cannabinoids.
Tetra Bio-Pharma Inc. today announced the retirement of Bernard Lessard as Chief Financial Officer and the appointment of Sabino Di Paola as his replacement effective May 15.
OTTAWA, May 09, 2019 (GLOBE NEWSWIRE) -- PANAG Pharma Inc. (PANAG), a wholly owned subsidiary of Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a bio-pharmaceutical company engaged in…
Panag Pharma Inc. today announced that its pilot clinical study to evaluate the tolerability and potential efficacy of its PPP003 ophthalmic drug in the treatment of indolent corneal ulcers in companion animals has been authorized by the Veterinary Drugs Directorate (VDD), Health Canada.
Tetra Bio-Pharma Inc. is pleased to announce that it completed today the previously-announced acquisition of Panag Pharma Inc. pursuant to a share purchase agreement dated January 30, 2019 between the Company and the shareholders of Panag.
Tetra Natural Health announces the arrival of twenty (20) containers, or more than 1.7 million cans, of its Hemp Energy Drink in Canada, the first 100% natural energy drink made from hemp in the country.
Tetra Bio-Pharma Inc. and Altus Formulation Inc. today announced the signing of a Joint Venture Agreement under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
Tetra Bio-Pharma Inc. is pleased to announce that, at a special meeting of shareholders held today, the shareholders of the Company voted in favor of an ordinary resolution to approve the previously announced acquisition of Panag Pharma Inc.
Tetra Bio-Pharma Inc. today announced that it has entered into a collaboration agreement with Ovensa Inc. to evaluate TRIOZANTM, a proprietary nanomedicine platform for targeted delivery of cannabinoids to brain tumor cells.